Application of immune checkpoint inhibitors combined with radiotherapy in non-small cell lung cancer
10.3760/cma.j.cn371439-20210126-00134
- VernacularTitle:免疫检查点抑制剂联合放疗在非小细胞肺癌中的应用
- Author:
Peiwei WANG
1
;
Yiming WENG
;
Xue CUI
;
Min PENG
Author Information
1. 武汉大学人民医院肿瘤中心 430060
- Keywords:
Immunotherapy;
Radiotherapy;
Carcinoma, non-small-cell lung
- From:
Journal of International Oncology
2021;48(11):678-682
- CountryChina
- Language:Chinese
-
Abstract:
The emergence of immune checkpoint inhibitors (ICIs) has greatly changed the treatment strategy of non-small cell lung cancer (NSCLC). Although ICIs are effective, there are still many patients who cannot benefit from immunotherapy alone. The current research direction focuses on the combination of multiple treatment schemes. Radiotherapy can upregulate immunogenic cell surface markers, and regulate the expressions of immune checkpoints. A large number of preclinical and clinical studies are exploring the efficacy and safety of ICIs combined with radiotherapy in various clinical stages of NSCLC, including radiotherapy timing, optimal dose, dose distribution and so on.
